The nation's top vaccine advisory panel is expected to debate on Thursday whether to delay the first dose of the hepatitis B ...
A group of advisers to the Centers for Disease Control and Prevention is preparing to vote on whether the agency should scrap ...
As RFK Jr.'s new vaccine panel ponders changing the hepatitis B vaccination schedule, some doctors recall past patients, ...
1dOpinion
The Journey To Hepatitis B Elimination Through Innovation, Early Testing, And Scientific Discovery
As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...
The three-dose hepatitis B vaccine has a long track record of safety, but rolling back recommendations could leave kids ...
GlobalData expects the chronic hepatitis B therapeutics market across major markets to climb from $1.5 billion in 2024 to ...
Vaccine advisers to the US Centers for Disease Control and Prevention may vote this week to make a major change to the ...
Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...
Richard Angell, CEO of the Terrence Higgins Trust, considers the success of opt-out HIV testing in A&E – and what it could ...
The Hepatitis B and C Therapeutics Market has entered a renewed growth cycle in 2024, led by innovative antiviral regimens, ...
Company preparing to initiate first-in-human Phase 1 study of CRMA-1001 in early 2026 nChroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback